Increased level of active GSK‐3β in Alzheimer’s disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration

The somatodendritic accumulation of hyperphosphorylated tau proteins is an early event preceding the appearance of neurofibrillary tangles (NFT) in Alzheimer’s disease (AD) and might be necessary for their formation. Glycogen synthase kinase‐3β (GSK‐3β) is a physiological kinase for tau that generates many tau phosphorylation sites identified in NFT and in other tau‐positive inclusions. We have studied the cellular distribution and the expression of the active form of GSK‐3β (GSK‐3 pTyr216) in AD patients, in argyrophilic grain disease and in diffuse Lewy body disease. By Western blotting analysis, a significant increase in the level of GSK‐3 (pTyr216) was observed in the frontal cortex of AD patients. A population of neurones showed a somatodendritic accumulation of GSK‐3 (pTyr216) but not of the inactive form of GSK‐3β (GSK‐3 pSer9). Most of these GSK‐3 (pTyr216)‐positive cells were positive for six different phosphotau epitopes known to be generated by GSK‐3β. By using a quadruple labelling method using GSK‐3 (pTyr216) and phosphotau immunolabelling combined with Gallyas and DAPI staining, we examined neurones containing a somatodendritic GSK‐3 (pTyr216) immunoreactivity at different stages of neurodegeneration. A majority of neurones at the pretangle stage without Gallyas‐positive inclusions were GSK‐3 (pTyr216) positive and this GSK‐3 (pTyr216) immunoreactivity remained in most cells containing Gallyas and phosphotau‐positive inclusions excepted in extracellular NFT. A GSK‐3 (pTyr216) immunoreactivity was present in argyrophilic grains but not in cortical Lewy bodies. These results directly suggest that the activity of GSK‐3β is increased in AD and that somatodendritic accumulation and activation of GSK‐3β is an early event preceding and accompanying the formation of NFT and of other tau‐positive inclusions.

[1]  Wendy Noble,et al.  Tyrosine 394 Is Phosphorylated in Alzheimer's Paired Helical Filament Tau and in Fetal Tau with c-Abl as the Candidate Tyrosine Kinase , 2005, The Journal of Neuroscience.

[2]  G. V. Van Hoesen,et al.  Phosphorylation of Tau by Fyn: Implications for Alzheimer's Disease , 2004, The Journal of Neuroscience.

[3]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[4]  H. Braak,et al.  A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads , 2004, Acta Neuropathologica.

[5]  A. Delacourte,et al.  Argyrophilic grain disease and Alzheimer's disease are distinguished by their different distribution of tau protein isoforms , 2002, Acta Neuropathologica.

[6]  I. Ferrer,et al.  Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration , 2002, Acta Neuropathologica.

[7]  A. Takashima,et al.  Role of GSK‐3β in Alzheimer's disease pathology , 2002 .

[8]  D. Dickson,et al.  Argyrophilic Grain Disease Is a Sporadic 4‐Repeat Tauopathy , 2002, Journal of neuropathology and experimental neurology.

[9]  I. Everall,et al.  Rapid Tyrosine Phosphorylation of Neuronal Proteins Including Tau and Focal Adhesion Kinase in Response to Amyloid-β Peptide Exposure: Involvement of Src Family Protein Kinases , 2002, The Journal of Neuroscience.

[10]  J. Woodgett,et al.  The active form of glycogen synthase kinase-3β is associated with granulovacuolar degeneration in neurons in Alzheimer's disease , 2002, Acta Neuropathologica.

[11]  G. Johnson,et al.  Glycogen Synthase Kinase 3β Is Tyrosine Phosphorylated by PYK2 , 2001 .

[12]  I. Grundke‐Iqbal,et al.  Hyperphosphorylation induces self-assembly of τ into tangles of paired helical filaments/straight filaments , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  René Hen,et al.  Decreased nuclear β‐catenin, tau hyperphosphorylation and neurodegeneration in GSK‐3β conditional transgenic mice , 2001 .

[14]  M. Mercken,et al.  Glycogen Synthase Kinase-3β Phosphorylates Protein Tau and Rescues the Axonopathy in the Central Nervous System of Human Four-repeat Tau Transgenic Mice* , 2000, The Journal of Biological Chemistry.

[15]  C. W. Scott,et al.  Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[16]  W. Blackstock,et al.  Phosphorylation Sites on Tau Identified by Nanoelectrospray Mass Spectrometry , 2000, Journal of neurochemistry.

[17]  A. Kimmel,et al.  The Novel Tyrosine Kinase ZAK1 Activates GSK3 to Direct Cell Fate Specification , 1999, Cell.

[18]  H. Braak,et al.  Distribution of Active Glycogen Synthase Kinase 3β (GSK-3β) in Brains Staged for Alzheimer Disease Neurofibrillary Changes , 1999 .

[19]  E. Mandelkow,et al.  Phosphorylation of tau protein by recombinant GSK‐3β: pronounced phosphorylation at select Ser/Thr‐Pro motifs but no phosphorylation at Ser262 in the repeat domain , 1999, FEBS letters.

[20]  J. Brion,et al.  Developmental expression and localization of glycogen synthase kinase-3β in rat brain , 1999, Journal of Chemical Neuroanatomy.

[21]  R. Jope,et al.  Insulin Transiently Increases Tau Phosphorylation , 1999, Journal of neurochemistry.

[22]  H. Band,et al.  Tau interacts with src-family non-receptor tyrosine kinases. , 1998, Journal of cell science.

[23]  E. Mandelkow,et al.  Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. , 1998, European journal of biochemistry.

[24]  H. Braak,et al.  Argyrophilic grain disease: frequency of occurrence in different age categories and neuropathological diagnostic criteria , 1998, Journal of Neural Transmission.

[25]  U. Wagner,et al.  Tau phosphorylation in transgenic mice expressing glycogen synthase kinase‐3β transgenes , 1997, Neuroreport.

[26]  A. Monsch,et al.  Argyrophilic grain disease: distribution of grains in patients with and without dementia , 1997, Acta Neuropathologica.

[27]  E. Braak,et al.  Distribution, Levels, and Activity of Glycogen Synthase Kinase‐3 in the Alzheimer Disease Brain , 1997, Journal of neuropathology and experimental neurology.

[28]  R. Hoffmann,et al.  Unique Alzheimer's disease paired helical filament specific epitopes involve double phosphorylation at specific sites. , 1997, Biochemistry.

[29]  K. Kosaka,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) , 1996, Neurology.

[30]  K. Imahori,et al.  Immunocytochemistry of tau phosphoserine 413 and tau protein kinase I in Alzheimer pathology , 1996, Brain Research.

[31]  K. Imahori,et al.  Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3β and cyclin-dependent kinase 5, a component of TPK II , 1996, Acta Neuropathologica.

[32]  B. Hyman,et al.  Glycogen synthase kinase 3α and 3β do not colocalize with neurofibrillary tangles , 1996, Neurobiology of Aging.

[33]  J. Brion,et al.  Cortical and brainstem-type Lewy bodies are immunoreactive for the cyclin-dependent kinase 5. , 1995, The American journal of pathology.

[34]  M. Goedert,et al.  Glycogen synthase kinase-3β phosphorylates tau protein at multiple sites in intact cells , 1995, Neuroscience Letters.

[35]  E. Vanmechelen,et al.  Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205 , 1995, Neuroscience Letters.

[36]  M. Goedert,et al.  Monoclonal antibody PHF‐1 recognizes tau protein phosphorylated at serine residues 396 and 404 , 1994, Journal of neuroscience research.

[37]  Simon Lovestone,et al.  Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells , 1994, Current Biology.

[38]  P. Cohen,et al.  Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. , 1994, The Biochemical journal.

[39]  J. Wood,et al.  The protein tyrosine kinase, fyn, in Alzheimer's disease pathology , 1993, Neuroreport.

[40]  G. Drewes,et al.  Glycogen synthase kinase‐3 and the Alzheimer‐like state of microtubule‐associated protein tau , 1992, FEBS letters.

[41]  K. Imahori,et al.  Phosphorylation sites on tau by tau protein kinase I, a bovine derived kinase generating an epitope of paired helical filaments , 1992, Neuroscience Letters.

[42]  J. Woodgett,et al.  Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: Generation of paired helical filament epitopes and neuronal localisation of the kinase , 1992, Neuroscience Letters.

[43]  E. Mandelkow,et al.  The switch of tau protein to an Alzheimer‐like state includes the phosphorylation of two serine‐proline motifs upstream of the microtubule binding region. , 1992, The EMBO journal.

[44]  K. Jellinger,et al.  Accumulation of abnormally phosphorylated τ precedes the formation of neurofibrillary tangles in Alzheimer's disease , 1989, Brain Research.

[45]  F. Gallyas,et al.  Silver staining of Alzheimer's neurofibrillary changes by means of physical development. , 1971, Acta morphologica Academiae Scientiarum Hungaricae.